Admin

Pfizer's revenue in the fourth quarter of 2025 was $17.56 billion, with non-COVID business growing by 9%. The full-year 2026 revenue guidance is $59.5-62.5 billion. | Earnings Report News

Pfizer's revenue in the fourth quarter of 2025 was $17.56 billion, with non-COVID business growing by 9%. The full-year 2026 revenue guidance is $59.5-62.5 billion. | Earnings Report News

``` On February 3, Pfizer’s 2025 full-year financial report showed the company demonstrating strong operational resilience during its strategic transformation phase. According to the financial report, total full-year revenue was $62.6 billion; excluding COVID-related products, its core business portfolio achieved 6% operating growth. Adjusted earnings per share reached $3.
Admin
Merck's full-year revenue for 2025 is $65 billion, up 1% year-over-year; its 2026 revenue guidance is $65.5 billion to $67 billion, below expectations|Earnings Report News

Merck's full-year revenue for 2025 is $65 billion, up 1% year-over-year; its 2026 revenue guidance is $65.5 billion to $67 billion, below expectations|Earnings Report News

On February 3, Merck released its financial results for the fourth quarter and full year of 2025. Driven by continued growth of Keytruda, increased contributions from new products such as Winrevair and Capvaxive, and steady performance in animal health, the company achieved full-year sales of $65 billion, up 1% year-on-year.
Admin